<>
Press Release
5 May 2009
New investment partnership to target medical diagnostic technology
A new investment partnership is looking to invest up to $10 million developing globally-focused medical diagnostics
businesses in New Zealand.
The partnership is between the New Zealand Venture Investment Fund and the private investment company, New Zealand
Diagnostics Ltd (NZDx). It aims to invest between $8 million and $10 million into new medical diagnostics ventures.
NZDx director William Randall said that the international diagnostics market is experiencing rapid growth and is worth
around US$30 billion.
“There are some very promising technologies emerging in New Zealand which could have considerable commercial potential.
As the cost of healthcare rises around the world, the sector is looking at ways to deliver better and more efficient
treatment, and new diagnostic technologies allow that.
“We are active investors in the sector. We have invested in two exciting new ventures – eBonz, which has developed 3D
anatomically based models of all joints in the human body, and Manawatu Diagnostics, which is developing human fertility
medical diagnostic technology.”
NZVIF chief executive Franceska Banga said the partnership was an exciting prospect given New Zealand’s strong
background in life sciences technology.
“New Zealand has a history of excellence in life sciences research. NZDxhas considerable experience in developing new
businesses and, in particular, considerable knowledge of the medical diagnostics sector.
“We believe there are significant investment opportunities in medical diagnostics technology in New Zealand. With this
partnership, we hope to see greater investment in new innovations which have the potential to advance to the commercial
stage in global markets.”
NZDx's partnership with NZVIF is through NZVIF’s Seed Co-Investment Fund. Through the fund, NZVIF is investing $40
million into early stage companies with strong potential for high growth, alongside investments made by its partners.
This is the ninth partnership NZVIF has entered into through the Seed Co-Investment Fund, although this agreement with
NZDx is replacing an earlier partnership with Chrysalis, a life sciences investment company. Through these partnerships,
NZVIF has to date invested over $17.6 million into 21 companies.
ends